Brian McNamara, Haleon CEO
November 10, 2022 02:32 PM EST
Pharma

Ha­le­on ups full-year guid­ance af­ter rocky spin­off from GSK

Nicole DeFeudis

Editor

Af­ter get­ting off to a rather rocky start in Ju­ly, GSK’s con­sumer health spin­off Ha­le­on is up­ping its full-year sales guid­ance on the heels of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Bio­gen makes cuts across its re­search unit, shift­ing fo­cus to ‘ex­ter­nal op­por­tu­ni­ties’

Bio­Marin turns to ex-Roche deal­mak­er James Sabry to build ‘next ver­sion’ of 27-year-old com­pa­ny

An­thos' de­tailed mid-stage da­ta back its an­ti­co­ag­u­lant, but can the drug suc­ceed where Bay­er's failed?

Chi­na's biotech boom is threat­en­ing US drug­mak­er­s' dom­i­nance

Te­va’s MS drug and gener­ics to add black box warn­ing for ana­phy­lax­is

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times